Chemotherapy of hormone refractory prostatic cancer
Stoter, G.; Jones, W.G.
Progress in Clinical and Biological Research 260: 123-125
1988
ISSN/ISBN: 0361-7742 PMID: 3129730 Document Number: 312623
Document emailed within 1 workday
Related Documents
Tsukamoto, T.; Fukui, I.; Kihara, K.; Goto, S.; Kitahara, S.; Kobayashi, T.; Kojima, S.; Oshima, H. 1996: Combined hormone-chemotherapy for stage D2 prostatic cancer: starting time of chemotherapy in relation to hormone therapy Hinyokika Kiyo. Acta Urologica Japonica 42(5): 351-356Burk, K.; Schultze-Seemann, W.; Jonas, D.; Rodeck, G. 1989: Weekly epirubicin in patients with hormone refractory prostatic cancer--a two-year follow-up Progress in Clinical and Biological Research 303: 277-285
Weissbach, L. 1992: Prospective randomized multicenter phase IIi study of treatment of hormone refractory prostatic cancer: mitomycin C vs. 4-epirubicin vs. estramustine phosphate Der Urologe. Ausg. a 31(1): 62
Fujinami, K.; Miura, T.; Takizawa, A.; Osada, Y. 2005: Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 51(1): 5-8
Ebert, T.; Bendhack, M.L. 1997: Prostatic carcinoma--diagnosis, hormone therapy, radio- and chemotherapy Der Urologe. Ausg. a 36(6): 570-577
Ngo, L.S.M.; Yeo, A.; Wong, A.S.C.; Tay, M.Hiang. 2007: Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore Annals of the Academy of Medicine Singapore 36(10): 811-814
Machida, T.; Ikemoto, I. 1987: Hormone therapy of male genital cancer (prostatic cancer) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(10): 2845-2852
Arena, F. 2008: Dutasteride in the treatment of hormone refractory prostate cancer Minerva Urologica e Nefrologica 60(2): 71-76
Roth, B.J. 1996: New therapeutic agents for hormone-refractory prostate cancer Seminars in Oncology 23(6 Suppl 14: 49-55
Smith, P.H.; Akdas, A.; Mason, M.K.; Richards, B.; Robinson, M.R.; de Pauw, M.; Sylvester, R. 1980: Hormone therapy in prostatic cancer Acta Urologica Belgica 48(1): 98-105
Wilkes, G.M. 2010: Cabazitaxel, a taxane for men with hormone-refractory metastatic prostate cancer Oncology 24(10 Suppl): 46-48
Ross, R.W.; Kantoff, P.W. 2007: Hormone-refractory prostate cancer: choosing the appropriate treatment option Oncology 21(2): 185-193; Discussion 194: 199-200
Haapiainen, R.; Rannikko, S.; Alfthan, O.; Adlercreutz, H. 1988: Pretreatment hormone levels in prostatic cancer Scandinavian Journal of Urology and Nephrology. Supplementum 110: 137-143
Dexeus, F.; Logothetis, C.J.; Samuels, M.L.; Hossan, E.; von Eschenbach, A.C. 1985: Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer Cancer Treatment Reports 69(7-8): 885-886
Wemeau, L.; Mazeman, E.; Blanckaert, J.; Delhay, J. 1972: Results of hormone treatment of prostatic cancer. 168 cases Acta Urologica Belgica 40(1): 101-105
Satthapong, D.; Tangjitgamol, S.; Manusirivithaya, S.; Pataradool, K. 2007: Chemotherapy in patients with recurrent or refractory epithelial ovarian cancer Journal of the Medical Association of Thailand 90(3): 411-419
Nikolaev, A.A.; Lutskiĭ, D.L.; Nikolaeva, N.N. 2000: Prostatic cancer: immunochemical control over chemotherapy Urologiia 3: 41-43
Murphy, G.P. 1987: To what degree is chemotherapy useful in the treatment of prostatic cancer Progress in Clinical and Biological Research 243b: 247-253
Yang, N-qin.; Wang, Y-xin. 2006: Current situation of researches on the molecule mechanism of hormone refractory prostate cancer Zhonghua Nan Ke Xue 12(6): 551-554
Kelly, W.K. 1998: Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer European Urology 34(Suppl): 18-23